Webster Bank N. A. Reduces Stock Position in Danaher Co. (NYSE:DHR)

Webster Bank N. A. decreased its holdings in shares of Danaher Co. (NYSE:DHRFree Report) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 49,792 shares of the conglomerate’s stock after selling 224 shares during the period. Danaher makes up about 1.4% of Webster Bank N. A.’s holdings, making the stock its 11th largest holding. Webster Bank N. A.’s holdings in Danaher were worth $11,519,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in DHR. Independence Bank of Kentucky lifted its stake in Danaher by 10.4% during the fourth quarter. Independence Bank of Kentucky now owns 3,775 shares of the conglomerate’s stock worth $873,000 after purchasing an additional 357 shares during the last quarter. Coastline Trust Co lifted its stake in Danaher by 5.2% during the fourth quarter. Coastline Trust Co now owns 9,446 shares of the conglomerate’s stock worth $2,185,000 after purchasing an additional 464 shares during the last quarter. Regent Peak Wealth Advisors LLC increased its holdings in shares of Danaher by 3.1% in the fourth quarter. Regent Peak Wealth Advisors LLC now owns 1,954 shares of the conglomerate’s stock worth $452,000 after buying an additional 59 shares during the period. Stonegate Investment Group LLC increased its holdings in shares of Danaher by 1.7% in the fourth quarter. Stonegate Investment Group LLC now owns 243,646 shares of the conglomerate’s stock worth $56,365,000 after buying an additional 3,970 shares during the period. Finally, Dupont Capital Management Corp increased its holdings in shares of Danaher by 13.6% in the fourth quarter. Dupont Capital Management Corp now owns 56,210 shares of the conglomerate’s stock worth $13,004,000 after buying an additional 6,725 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 0.7 %

DHR opened at $244.26 on Thursday. The firm has a 50-day simple moving average of $248.92 and a two-hundred day simple moving average of $230.38. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00. The company has a market capitalization of $180.88 billion, a PE ratio of 38.23, a price-to-earnings-growth ratio of 3.77 and a beta of 0.83. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHRGet Free Report) last released its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating the consensus estimate of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business had revenue of $6.41 billion during the quarter, compared to the consensus estimate of $6.10 billion. During the same quarter in the prior year, the firm earned $2.87 EPS. The business’s revenue was down 10.2% on a year-over-year basis. Analysts forecast that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend is Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is 16.90%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. Insiders sold 32,957 shares of company stock valued at $8,265,802 in the last 90 days. Insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on DHR. Raymond James boosted their price target on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Royal Bank of Canada boosted their target price on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. TheStreet upgraded Danaher from a “c+” rating to a “b-” rating in a research note on Friday, December 8th. JPMorgan Chase & Co. upped their price objective on Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. Finally, Wolfe Research assumed coverage on Danaher in a research note on Wednesday, December 13th. They issued a “peer perform” rating for the company. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $266.00.

Get Our Latest Research Report on DHR

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

See Also

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.